SelectQuote, Inc. (SLQT) embodies the classic fintech rollercoaster: a direct-to-consumer insurance marketplace that rode the digital wave of the early pandemic years to explosive growth, only to grapple with post-boom realities like margin compression and operational resets. Since its high-profile SPAC debut in October 2020 via a merger with Chamberlain Parent Ltd.—valuing it at over $6 billion at peak—SLQT has seen its stock price plummet from highs above $30 to recent lows hovering around current levels. Yet, beneath the volatility, revenue engines are revving up again, profitability is flickering back, and a lone insider buy signals quiet confidence. As we unpack the fundamentals, the narrative shifts from survival mode to cautious reacceleration, with analysts eyeing substantial upside from here.
Revenue Trajectory: From Pandemic Surge to Steady Climb
SelectQuote’s revenue story is one of hyper-growth followed by a necessary cooldown, now bending toward expansion. Starting from $337 million in 2019, sales rocketed 57% to $529 million in 2020 and nearly doubled again to $930 million in 2021, fueled by lockdown-driven demand for online insurance quotes in Medicare, life, and auto segments. This wasn’t just volume; revenue per employee soared from $187,000 in 2019 to a peak of $282,000 in 2021, highlighting operational leverage in a scalable lead-generation model. Why does this matter? Revenue per employee is a proxy for efficiency in service-heavy businesses like SLQT, where human agents drive conversions.
But 2022 brought a 18% revenue drop to $764 million as pandemic tailwinds faded and healthcare enrollment cycles normalized—echoing broader insurtech challenges post-COVID. Recovery kicked in: 2023 revenue jumped 31% to $1.00 billion, 2024 accelerated 32% to $1.32 billion, with per-employee productivity hitting $308,000 (up 29% from 2023). Analyst forecasts pencil in 16% growth to $1.53 billion in 2025 and another 9% to $1.66 billion in 2026, suggesting sustained demand in an aging U.S. population favoring Medicare Advantage plans, where SLQT holds strong positioning. Revenue per share mirrors this, climbing from $4.66 in 2022 to a projected $9.42 in 2026—a 102% rise over four years—bolstering the case for undervaluation.
Profitability Swings: Losses Narrow, Margins Rebound in Sight
Profitability tells a bumpier tale, correlating tightly with gross margins and one-time hits. Gross margins peaked at 70.9% in 2021 but cratered to 40.4% in 2022 amid higher customer acquisition costs and healthcare segment investments—critical because margins reflect pricing power in competitive lead-gen spaces. EBT margins flipped from 17% positive in 2021 to a brutal -51% loss that year ($390 million red ink), driven by $75 million in depreciation (up 284% from 2020), likely tied to tech platform buildouts and intangible impairments post-SPAC.
Net income followed suit: $125 million profit in 2021 swung to -$298 million loss (a 338% deterioration), then narrowed sequentially—-$58 million (-80% less loss), -$34 million (-42% improvement), and back to $48 million profit in 2024 (a 241% swing to positive). ROE, a key gauge of shareholder value creation, bottomed at -56% in 2021 but clawed to 7.5% in 2024. Forecasts show $64 million net income in 2025 (34% growth) before a puzzling -$16 million dip in 2026—perhaps conservative modeling of cyclical risks. Earnings per share track this: from -$1.81 in 2022 to $0.14 in 2024, eyed at -$0.10 in 2025. These swings underscore SLQT’s transition from growth-at-all-costs to disciplined profitability, vital for rebuilding investor trust.
Balance Sheet Resilience Amid Debt Overhang
SLQT’s balance sheet reveals a company deleveraging after aggressive expansion. Total debt ballooned from $312 million in 2020 to $706 million peak in 2022 (127% increase), funding working capital that swelled to $1.14 billion in 2021. Net debt hit $641 million in 2024, but recent cuts to $385 million total debt (down 44% from 2023’s $683 million) signal cleanup—important for ROIC, which ticked up to 4.6% in 2024 from negative territory. Shareholder equity dipped to $317 million in 2024 (down 9% from 2023) but is projected to rebound, with book value per share leaping 74% to $3.27.
Free cash flow per share remains erratic—negative through most years, but a slim positive $0.02 in 2024 after -$2.27 low in 2022—highlighting capex discipline (now ~$11-25 million annually). EV/Sales compressed from 5.6x in 2020 to 0.9x projected, screaming cheapness relative to sales growth. This fortifies the moat as SLQT eyes Medicare open enrollment seasons, where historical spikes have driven 30%+ revenue pops.
Stock Price Saga: Boom, Bust, and Bottom Fishing
SLQT’s share price mirrors the fundamentals’ drama. From 2020’s $15.76-$29.00 range amid SPAC hype, it spiked to $7.72-$33.00 in 2021 (high up 14% from prior), then imploded: 2022 low $0.51 (97% drop from 2021 low), 2023 $0.62-$2.94. A 2024 rally to $1.03-$4.46 (high +52%) fizzled, with 2025 projected $1.33-$6.86 giving way to today’s close near recent troughs.
This disconnect? PS ratio plunged from 5.4x in 2018 to 0.27x in 2024 (versus peers at 2-4x), PB from 39x to 1.2x, and PE swung from 24x to 17x on 2024 earnings. Shares outstanding crept 3% to 176 million, dilutive but manageable. Compared to revenue doubling since 2022, the stock lags massively—trading at 0.11x 2026 sales estimates. Analyst targets reflect this: low implies ~40% upside, average ~230%, high ~460% from recent levels, baking in earnings recovery and multiple expansion.
Insider Signals and Strategic Context
Insider activity is sparse but telling: a single director buy of 4,000 shares on March 14, 2025, for $14,460—no sells across 2025-early 2026. In a sub-$1 stock, this vote-of-confidence from the board (total insider buys $14,460) correlates with bottoming patterns, often preceding 50-100% rebounds in beaten-down names. No sales amid recovery hints alignment.
Major events contextualize: The 2020 SPAC rode insurtech fever (think Lemonade, Hippo), but 2021-22 rate hikes and healthcare policy shifts (e.g., Medicare Advantage scrutiny) hammered margins. Recent tailwinds? SLQT’s 2023 pivot to senior-focused healthcare (80%+ revenue) aligns with 10,000 Baby Boomers retiring daily, plus AI-enhanced quoting efficiency.
Outlook: Re-Rating on Growth Revival?
Looking ahead, SLQT’s narrative pivots to “proven survivor.” Revenue chugging toward $1.7 billion by 2026, margins stabilizing at 4% EBT (from -2% in 2024? Wait, data shows 3.2% in 2024), and debt shedding position it for FCF positivity if capex holds. Risks loom—healthcare regulation, competition from Policygenius—but ROA/ROE trends (2% and 7.5%) suggest compounding ahead. With targets implying 40-460% pops, the stock could double on 2025 earnings beats alone, especially if open enrollment delivers. For patient investors, this is the story of a phoenix mid-rise: buy the dip on insider faith and demographic inevitability.
(Word count: 1,128)